Summary of Financial Performance:
Waters Corporation reported strong Q2 2025 results with sales of $771 million, up 9% reported and 8% in constant currency. Recurring revenue grew 11%, driven by 9% service growth and double-digit chemistry growth. Non-GAAP EPS was $2.95, up 12% year-over-year, while GAAP EPS was $2.47. Gross margin stood at 58.3%, and adjusted operating margin was 29.1%. Pharma led growth at 11%, while Industrial grew 6%. Academic and government declined 3%. Instruments grew 4%, aided by robust performance in LC and MaxPeak systems. Free cash flow was $159 million, with $100 million of debt reduction planned for H2 2025. Full-year 2025 constant currency sales growth guidance was raised to 5.5% to 7.5%, with adjusted EPS guidance increased to $12.95-$13.05 (9%-10% growth).
Company Outlook & Strategy:
Waters raised its full-year 2025 guidance, citing strong momentum in its core business and the pending acquisition of BD Biosciences and Diagnostic Solutions. The company expects a combined annualized CAGR of 7% in revenue and mid-teens EPS growth from 2025 to 2030. It plans to leverage synergies from the BD acquisition, including $345 million in EBITDA synergies ($200 million in cost savings and $290 million in revenue synergies). Waters is focused on long-term growth vectors, including bioanalytical characterization, bioseparations, and diagnostic mass spectrometry.
Key Industry Trends:
- Pharma and CDMO Growth: Strong replacement activity and new product adoption in large pharma and CDMO segments.
- PFAS Testing: Continued high growth in PFAS-related applications, up over 50% year-over-year.
- E-commerce Expansion: E-commerce now accounts for over 40% of chemistry revenue.
- Government and Academic Weakness: U.S. academic and government funding headwinds persist, alongside softness in drug discovery.
- Regulatory and Diagnostic Shifts: Increasing adoption of mass spectrometry in diagnostics and emerging demand for microbiology QA/QC in pharma.
Operational Highlights:
- Product Innovation: Alliance iS sales grew 300% year-over-year; Xevo TQ Absolute platforms grew 40%. The newly launched TQ Absolute XR demonstrated significant robustness improvements, enabling entry into DMPK laboratories.
- Regional Performance: Asia led growth with 14%, including double-digit growth in China, India, and Japan. Europe grew 8%, while the Americas grew 2%, hindered by academic/government softness.
- Service Penetration: Service plan attachment rose 200 basis points in H1 2025 to 52%.
- BD Acquisition: Waters is accelerating its entry into high-growth adjacencies, leveraging BD’s microbiology and flow cytometry expertise.
Challenges & Risks:
- Macro Sensitivity: Weakness in macro-sensitive TA segments (e.g., polymer and materials testing) and U.S. academic/government funding pressures.
- Tariff Impact: Tariff surcharges impacted gross margin, though conditions have improved slightly.
- Integration Risks: Execution risk tied to the integration of BD Biosciences and Diagnostic Solutions and delivery of synergies.
- Temporary BD Headwinds: BD Biosciences faced three temporary headwinds: pharma drug discovery softness, microbiology supply chain issues, and U.S. export bans to China for flow cytometry products.
Key Analyst Questions & Responses:
- LC Replacement and Competitive Dynamics: Waters noted strong replacement activity, particularly in large pharma and CDMO segments, aided by Alliance iS (300% growth). The Xevo TQ Absolute XR showcased increased robustness, supporting DMPK adoption.
- Mass Spec in Microbiology: Waters highlighted opportunities in microbial identification and sterility testing using mass spec, leveraging BD’s installed base and sales channels. FDA strategy for microbiology products and timelines for potential launches are being developed, with integration processes set to accelerate post-deal close.
This summary concisely captures the critical financial, strategic, and operational insights shared during the earnings call. Let me know if you need further clarification on any section!